A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

NCT06319118 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Salivation in Parkinson's Disease

Interventions

DRUG: Placebo
DRUG: dihydroergotine mesylate sustained-release tablets

Sponsor

Second Affiliated Hospital of Soochow University